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exposure to endocrine Disrupting 
chemicals in the Dutch general 
population is associated with 
adiposity-related traits
thomas p. van der Meer  1, Martijn van faassen2, André p. van Beek1, Harold Snieder  3, 
ido p. Kema2, Bruce H. R. Wolffenbuttel  1 & Jana V. van Vliet-ostaptchouk1,3,4 ✉
endocrine Disrupting chemicals (eDcs) have been linked to a variety of cardiometabolic diseases. Yet, 
few studies have investigated the exposure to eDcs and cardiometabolic health taking lifestyle into 
account. We aimed to assess exposure to five parabens, three bisphenols and thirteen metabolites 
of in total eight phthalates in a general Dutch population and to investigate their association with 
cardiometabolic traits. In 662 adult subjects from the population-based Lifelines cohort, 21 EDC 
analytes were measured in 24-hour urine collected in 2012, using LC-MS/MS. Association analyses 
between cardiometabolic traits and eDc concentrations were performed using multivariate linear 
models adjusting for age, sex, education, smoking, diabetes, physical activity and caloric intake. 
Quartile analyses were performed to assess linearity. Bisphenol A, four parabens and eight phthalate 
metabolites were detected in 84-100% of the samples. Adjusted associations for MiBP and MBzP and 
adiposity-related traits were robust for multiple testing (Beta’s, BMI: 1.12, 2.52; waist circumference: 
0.64, 1.56, respectively; FDR < 0.009). Associations for triglyceride, HDL-cholesterol, glucose and blood 
pressure were not. Linearity was confirmed for significant associations. Exposure to EDCs in the Dutch 
population is ubiquitous. We found direct associations between phthalates and adiposity-related traits. 
Prospective studies are needed to confirm these findings.
During the past decades, cardiovascular diseases (CVD) and type 2 diabetes (T2D) have risen to epidemic pro-
portions1,2. These diseases are responsible for severe complications including myocardial infarction, stroke, blind-
ness, lower limb amputation and renal failure, and are strongly correlated with a collection of asymptomatic 
cardiometabolic abnormalities such as (central) obesity, impaired glucose tolerance, elevated triglycerides, a low 
HDL-cholesterol, and hypertension3,4. A combination of at least three of the above stated cardiovascular abnor-
malities defines the metabolic syndrome (MetS)1. Risk factors include a combination of genetic predisposition 
and lifestyle (e.g. lack of physical activity, imbalanced diet).
Meanwhile, a wide variety of synthetic chemicals have been introduced in our environment, some of which 
have been shown to cause metabolic disruptions in animal and human studies5. Endocrine Disrupting Chemicals 
(EDCs) such as parabens, phenols and phthalates have been shown to be associated with the MetS6,7, obesity8,9 
and T2D10,11. These EDCs have in common that they are widely used as preservatives and plasticizers and can 
therefore be found in a wide variety of consumer products. Exposure occurs through ingestion, inhalation, and 
dermal contact12,13. Although parabens, phenols and phthalates have in common that they are metabolized and 
excreted fairly quickly (i.e. half-lives <24 h) and therefore are considered non-persistent14–16, exposure is ubiqui-
tous throughout life and reported to be global17–20. However, to date little is known about exposure to these EDCs 
in the general Dutch population.
Common parabens, such as methyl paraben (MeP), ethyl paraben (EtP), propyl paraben (PrP), n-butyl para-
ben (n-BuP) and benzyl paraben (BzP) are widely used as antimicrobial preservatives in food, cosmetics, personal 
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care products (e.g. soaps, makeup, lotions and sanitary products) and pharmaceuticals. These compounds 
are known to possess weak estrogenic properties. Adverse effects of parabens on lipid metabolism have been 
described in vitro and in vivo21,22. Bisphenol A (BPA) is a chemical that is produced in one of the highest volumes 
worldwide. It can be found in a wide range of products such as plastic bottles and food packaging, personal care 
products and paper receipts. BPA has weak estrogenic and anti-androgenic effects23,24. and has been associated 
with adverse effects on T2D25,26, CVD25, obesity27, and the MetS26. Due to the restriction of BPA in children’s 
toys by the European Union and growing consumer concern, BPA is increasingly being replaced by analogues 
such as Bisphenol F (BPF) and Bisphenol S (BPS) creating “BPA-free” products28. Yet, these analogues appear 
to be at least as deleterious for the endocrine system as BPA29. Phthalates are known for their anti-androgenic 
effects and can be divided in Low-Molecular-Weight (LMW) and High-Molecular-Weight (HMW) phthalates. 
LMW-phthalates are most commonly used in food products, cosmetics, personal care products and medications, 
whereas HMW-phthalates are used as soft plastics in food packaging, medical tubing and toys30–32. Associations 
of phthalates have been found with high body mass index (BMI) and waist circumference9, high blood pres-
sure7,33, (pre-)diabetes10,11, and the MetS6. Yet, associations of parabens, bisphenols and phthalates with cardi-
ometabolic outcomes are not consistently observed in epidemiological studies. Next to positive findings in the 
studies mentioned above, other studies have not been able to confirm these associations34–37.
In this study, we assessed the exposure to the most common non-persistent EDCs including five parabens, 
three bisphenols and thirteen metabolites of in total eight different phthalate diesters in a general Dutch popula-
tion and investigated potential associations between these EDCs and cardiometabolic traits.
Methods
Study population. This study consisted of 662 native Dutch adult subjects randomly selected as a subsam-
ple from the Lifelines Cohort Study with available data on physical examination, biochemical measurements, 
extensive questionnaires, and 24-hour (24 h) urine samples. Lifelines is a population-based cohort study, of which 
the cohort profile has been described elsewhere38, and is representative for the north of the Netherlands39. The 
Lifelines Cohort Study is conducted in accordance with the Declaration of Helsinki and the research code of the 
University Medical Center Groningen (UMCG). Before study entrance, participants signed an informed consent. 
The study was approved by the UMCG medical ethics review committee.
clinical measurements. In Lifelines, measurements were performed by a trained research nurse using a 
standardized protocol. Height, weight and waist circumference were measured to the nearest 0.5 cm, 0.1 kg, and 
0.5 cm, respectively. Waist circumference was measured in standing position, with a tape measure at the level 
midway between the lower rib margin and the iliac crest. Blood pressure was measured automatically (Dinamap 
PRO 100V2) in supine position every minute for 10 minutes, after which the average of the last three measure-
ments was taken for both systolic and diastolic blood pressure. BMI was calculated as (weight (kg)/height (m)2). 
Per individual, blood was collected in fasting state and glucose, triglycerides and HDL- cholesterol measurements 
were performed on the same day. Glucose (mmol/L) was measured using a hexokinase method. HDL-cholesterol 
(mmol/L) and triglycerides (mmol/L) were measured using an enzymatic colorimetric method and a colorimetric 
UV method, respectively, using a Roche Modular P chemistry analyser (Roche, Basel, Switzerland). We aimed to 
measure EDC exposure which is representative for daily exposure. Therefore, participants collected all their urine 
over a period of 24 h during normal living conditions without any specific dietary instructions. Containers were 
specifically supplied for this purpose and were accompanied by oral and written instructions. Aliquots of urine 
were stored at −80 °C for later laboratory assessment38.
Assessment of potential confounding factors. Extensive information was gathered using question-
naires on demographic characteristics and lifestyle as described somewhere else38. Smoking status and Type 2 
Diabetes diagnosis were assessed using a questionnaire and categorized as yes or no (reference group). Education 
level was measured according to the International Standard Classification of Education with a single-item ques-
tion on the highest educational level achieved40, and classified as low (no education, primary education, lower 
or preparatory vocational education, or lower general secondary education), medium (intermediate vocational 
education or apprenticeship, or higher general secondary education or pre-university secondary education) or 
high (reference group) (higher vocational education, or university). Physical activity was assessed using the short 
questionnaire to assess health-enhancing physical activity (SQUASH), which is extensively described elsewhere41. 
In short, it includes questions on time and effort of activities including commuting, leisure-time, household, work 
and school. A total activity score is calculated by multiplying the total minutes of activity per week by its intensity 
score. Caloric intake was calculated based on the Lifelines Diet Score, a 110-item food frequency questionnaire, 
and expressed as total amount of kilocalories per day over the previous month and is therefore a general average42.
Paraben, bisphenol and phthalate measurements and 24 h calculations. The parabens MeP, EtP, 
PrP, n-BuP and BzP, the bisphenols BPA, BPF and BPS and metabolites of dimethyl phthalate (DMP), diethyl 
phthalate (DEP), di-iso-butyl phthalate (DiBP), di-n-butyl phthalate (DnBP), di-(2-ethyl-hexyl) phthalate 
(DEHP), butylbenzyl phthalate (BBzP), di-iso-nonyl phthalate (DiNP), and di-iso-decyl phthalate (DiDP) were 
analysed in 24 h urine samples using two offline isotope dilution liquid chromatography tandem mass spectrom-
etry (LC-MS/MS) technology, for which the full analytical methods have been described elsewhere43. In short, the 
aliquot was homogenized before subsamples were taken. For both methods a Phenomenex Kinetex Phenyl-Hexyl 
2.1 × 100 mm, 1.7 μm was used at 40 °C in combination with a Waters XEVO TQ-S triple quadrupole system 
using negative electrospray ionization. Transitions and qualitative and quantitative ions have been published ear-
lier43, and are reproduced here in Supplementary table 1a and 1b for completeness. Stable isotope labelled internal 
standards were used (when available 13 C labelled, otherwise deuterium labelled). For phenols, the mobile phase 
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consisted of 0.2 mM ammonium fluoride in 10% methanol in water (buffer A) and methanol (buffer B). For 
phthalates, 0.1% formic acid in 10% acetonitrile was used as mobile phase A and 0.1% formic acid in acetonitrile 
as mobile phase B. The flow rate for both methods was 0.4 mL/min. Runtimes were 7 minutes and 8 minutes per 
sample for the phenol and phthalate method, respectively.
A limit of detection (LOD) was calculated as “3.3*S0/b”, where S0 is the standard deviation of the response 
and b the slope of the calibration curve. The limit of quantification (LOQ) was set where the imprecision was 
≤20% and the signal to noise ratio was >10 on six days. Urinary excretions of EDCs per 24 h (ng/24 h) were 
calculated by multiplying the measured concentrations of EDCs (ng/mL) by the total urinary volume (mL) of 
collected urine in 24 h. This way, we corrected for liquid intake and urine dilution. To assess total exposure of 
parabens, bisphenols and phthalates, aggregated concentrations were calculated. First measured compounds were 
converted to molar concentrations by dividing the measured total excreted EDCs per 24 h with the respective 
molecular weight and expressed in nmol, using the formula: “molar concentration = raw *(1/molecular weight) 
*10^3”. Subsequently, phthalate molar concentrations were calculated by the sum of their respective metabolites 
(DEHP = MEHP + MnHP + MEHHP + MEOHP + MECPP; DiNP = MiNP + MHiNP). Phthalates with a sin-
gle metabolite are expressed as its metabolite (DMP as MMP, DEP as MEP, DiBP as MiBP, DnBP as MnBP, BBzP 
as MBzP, and DiDP as MiDP). In addition, the respective phthalates were added to calculate the concentration 
of LMW-phthalates (DMP, DEP, DiBP and DnBP) and HMW-phthalates (DEHP, BBzP, DiNP, and DiDP). Total 
bisphenol exposure was calculated by summing its molar concentrations (BPA, BPF and BPS), as was done for 
total paraben exposure (MeP, EtP, PrP, n-BuP and BzP).
Analytical approach. Exposure to EDCs was assessed by the number of individuals in which EDC concen-
trations were above the LOD and are shown as ratio of the full population (i.e. number of individuals with EDC 
concentration >LOD/total population * 100%). Concentrations and distribution of raw and total excreted EDCs 
per 24 h were shown as 25th, 50th (median), 75th quartile and maximum.
Next, we aimed to test whether exposure to EDCs was associated with cardiometabolic traits. As the LOQ 
indicates a threshold at which an analyte can be precisely measured, only EDCs which were detected above LOQ 
in at least 50% of the samples (i.e. EDC > LOQ in n > 331) were included in these analyses. For concentrations 
between LOD and LOQ, the value generated by the LC-MS/MS was used. Concentrations below LOD were 
imputed with the LOD divided by the square root of two (LOD/√2). Assumptions of linear regression were tested 
before analysis. Due to a right-skewed distribution, all EDCs and triglycerides were log10-transformed before 
analyses. Fasting glucose can be affected by diabetes. Therefore, individuals which reported being diabetic (n = 8), 
or with a fasting glucose which was ≥7.0 mmol/L (n = 41) were excluded from association analyses for EDCs 
and glucose. Associations were tested using two multivariate linear regression models. As EDCs have shown to 
differ between age and sex10,44, these factors have been adjusted for in the base model. Further, we assessed the 
robustness of associations by additionally correcting for factors known to be associated with EDC concentrations 
or cardiometabolic traits in the full model. EDC concentrations have been shown to differ between level of edu-
cation, diabetes and smoking status10,45–47. Further, the effect of lifestyle on cardiometabolic traits was taken into 
account in the full model by adjusting for caloric intake and physical activity.
Some associations between EDCs and cardiometabolic traits have been shown to follow a nonmonotonic 
dose-response curve48,49. In order to accommodate potential non-linear effects and test the robustness of our 
analysis, we categorized EDC exposure into quartiles and repeated the full multivariate linear model. In these 
quartile analyses, the quartile including individuals with the lowest exposure (quartile 1) was taken as reference 
group.
As this study includes many different EDCs, multiple testing was taken into account using Benjamini and 
Hochberg False Discovery Rate (FDR < 0.05) for all individual tests within the respective cardiometabolic trait. 
All analyses were performed in R software version 3.5.350.
Results
Detection of endocrine disrupting chemicals in a general dutch population. The study population 
consisted of slightly more females (58%) with a mean age of 46 years. Regarding the criteria for the MetS, mean 
values of cardiometabolic traits were well within the healthy range (Table 1). Concentrations of detected EDCs 
in Lifelines are shown in Table 2. The parabens MeP, EtP, and PrP, were detected above LOD in ≥93% of the sub-
jects, whereas n-BuP and BzP were detected in 86% and 5%. of the cases, respectively. Of the bisphenols, BPA was 
detected in 95% of the samples, followed by BPF (52%) and BPS (9%). Of the phthalate metabolites, MEP, MiBP, 
MnBP, MEHHP, MEOHP, MECPP and MBzP were detected in all samples. MEHP, MMP, MnHP, MiDP, and 
MiNP were detected in 84%, 53%, 21%, 10% and 1% of the samples, respectively. MHiNP was detected in none 
of the samples and is therefore not displayed. Only EDCs detected above LOQ in >50% of the population were 
included in further analyses (phenols: MeP, EtP, PrP, and BPA; phthalates: MEP, MiBP, MnBP, MEHP, MEHHP, 
MEOHP, MECPP, and MBzP).
Associations between endocrine disrupting chemicals and adiposity-related traits. Figure 1 
presents association analyses between urinary EDC concentrations and adiposity-related traits. The base model, 
which corrects for sex and age, showed direct associations for BPA, MEP, MiBP, MECPP and MBzP and BMI (all 
p < 0.05). When additionally correcting for level of education, smoking, diabetes, physical activity and caloric 
intake in the full model, the associations for BPA and MEP lost significance (p ≥ 0.05). Effect sizes for MiBP (Beta: 
1.12, p < 0.0001) and MECPP (B: 0.65, p = 0.031) were robust to the additional adjustments, whereas the effect 
size for MBzP increased (Bbase:0.45, p = 0.0099; Bfull: 0.64, p = 0.0006). Waist circumference showed associations 
to similar EDCs, with direct associations for BPA, MEP, MiBP and MBzP in the base model. Of these associa-
tions, BPA (B: 0.83, p = 0.042) and MiBP (2.52, p = 0.0002) remained robust to additional adjustments in the full 
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model. Like BMI, the effect size of MBzP increased in the full model (Bbase: 1.03, p = 0.0261; Bfull: 1.56, p = 0.001) 
The associations for MiBP and MBzP and both adiposity-related traits remained significant after adjusting for 
multiple testing (FDR:≤0.008). Estimates, confidence intervals, raw- and FDR-adjusted p-values are presented in 
Supplementary tables 2a,b.
Associations between endocrine disrupting chemicals and other cardiometabolic traits. 
Associations between EDCs and lipids are presented in Fig. 2. When adjusting for age and sex, HDL-cholesterol 
showed an inverse relation with MEP (B: −0.03, p = 0.0168). Although this association weakened in the full 
model, it remained significant (B: −0.02, p = 0.0391). For triglycerides, we found inverse associations with MEHP 
(B: −0.01, p = 0.0106) and MECPP (B: −0.04, p = 0.0089). After adjusting for additional variables both effects 
weakened, resulting in the association with MEHP becoming non-significant and the one with MECPP reduc-
ing in effect size (−0.03, p = 0.0417). None of the associations between lipids and EDCs survived the correction 
for multiple testing (all FDR > 0.05). Glucose and blood pressure were not associated with any of the EDCs. 
Estimates, confidence intervals and p-values can be found in Supplementary Table 2c–g.
Linearity of associations between endocrine disrupting chemicals and cardiometabolic traits. 
To evaluate if associations between continuous EDCs and cardiometabolic traits followed a linear relationship, 
EDCs were categorized into quartiles after which association analyses were repeated taking the first quartile (i.e. 
lowest exposure) as reference group. The results are presented in Supplementary Table 3a–d. For obesity-related 
traits, all significant associations originated from the third (versus first) or fourth (versus first) quartile. Although 
MiBP showed an association between its second versus first quartile, the effect sizes increased with higher quar-
tiles confirming linearity (Beta’s; BMI: second: 1.03, third: 1.45; fourth versus first: 1.91; waist circumference: sec-
ond: 2.76; third: 3.64; fourth versus first: 4.76). For lipids, significant associations originated solely from third or 
fourth EDC quartiles for all but MEHHP and triglycerides (second versus first quartile, B: 0.06, p-value: 0.0188). 
The second quartile versus first quartile of MnBP and EtP were associated for diastolic and systolic blood pres-
sure, respectively. Although MiBP showed significant associations with systolic blood pressure for its highest 
quartiles, the association with the third quartile (versus first) was much stronger compared to that of the fourth 
quartile (versus first; B: 3.48, 2.72, respectively). No associations between EDCs and glucose were found in the 
quartile analysis.
Discussion
In this study, exposure to five parabens, three bisphenols and thirteen metabolites of in total eight different phtha-
late diesters was assessed in 24 h urine samples of a general Dutch population. Next, we investigated potential 
associations between the EDCs which were quantified in at least 50% of the population and cardiometabolic 
traits, adjusting for risk factors including age, sex, education, smoking, diabetes status, physical activity and die-
tary intake.
Four parabens, BPA and more than half of the phthalate metabolites were detected in at least 90% of the 24 h 
urine samples, suggesting a ubiquitous exposure to these compounds in a general population from Northern 
Netherlands. To date, only two studies have examined a similar set of EDCs in the Netherlands, using a pop-
ulation of pregnant women from the Generation R study51,52. The most recent study by Philips et al. showed 
Characteristics
Sex = Male (%) 280 (42)
Age (years) 45.8 (13)
BMI (kg/m2) 24.823,28 *
Waist circumference (cm) 89.8 (12)
Fasting Glucose (mmol/L) 5.0 (0.6)
Triglycerides (mmol/L) 0.92 [0.7, 1.3]*
HDL Cholesterol (mmol/L)♂ 1.36 (0.3)
HDL Cholesterol (mmol/L)♀ 1.68 (0.4)
Diastolic BP (mmHg) 71 (9.0)
Systolic BP (mmHg) 120 (13)
Smoking (yes, %)** 114 (17)





Table 1. Characteristics of the study population drawn from the Lifelines cohort (n = 662). Values are 
expressed as mean (standard deviation) or median [inter-quartile range]. *non-normal distribution, given 
as median [interquartile range]; ** NA:9; *** NA: 14; ♂male, ♀female. Glucose and lipids are in expressed in 
mmol/L. Abbreviations: SD, standard deviation; BMI, Body Mass Index; LDL, Low-Density Lipoprotein; HDL, 
High-Density Lipoprotein; BP, Blood Pressure; NA, not available.
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similar (i.e. <15% difference between medians) concentrations for BPA (median [25th; 75th quartile]: 1.90 [0.96; 
3.63] vs 1.66 [0.72; 3.56] ng/mL), MiBP (19.7 [12.1; 34.2] vs 21.6 [9.55; 45.9] ng/mL), MnBP (17.5 [10.8; 29.0] 
vs 16.2 [7.01; 31.2] ng/mL), and MBzP (5.84 [3.27; 11.0] vs 6.59 [3.07; 12.9] ng/mL). However, in current study 
we detected lower concentrations of BPF (0.24 [<LOD; 0.68] vs 0.57 [0.30; 1.29 ng/mL), MMP (0.48 [<LOD; 
1.20] vs 5.43 [2.75; 9.88] ng/mL), MEP (47.1 [20.0; 132] vs 138 [41.2; 487 ng/mL), and all DEHP metabolites 
(9.12 [6.20; 14.0] vs 12.0 [5.83; 23.2]; 6.15 [4.10; 9.60] vs 7.81 [3.53; 15.5]; 10.3 [6.60; 16.0] vs 16.4 [8.26; 31.8] 
ng/mL, MEHHP, MEOHP, MECPP, respectively). The observed discrepancies could be due to several reasons. 
First, the study population differed (i.e. general population vs pregnant women). Second, urine samples from the 
Generation R study were collected in 2004–2005, whereas samples from the current study were collected in 2012. 
During this time, EDCs used in consumer products could have changed, partly due to a rise in public awareness 
of the potential health effects of EDCs. A study investigating temporal trends of phthalates over similar time 
period (2001–2010) in NHANES showed a decrease urinary phthalate concentrations similar to our findings53. 
Third, Philips et al. determined EDC concentrations in spot urine. Although Christensen et al. showed spot urine 
samples to be roughly comparable with 24 h urine samples, several studies detected higher EDC concentrations 
in spot urine compared to 24 h urine54–56.
In general, we detected EDCs concentrations in the same ranges as other European countries19,57–64, although 
there are differences and variation in reported levels between studies and countries. Also, the Center of Disease 
and Control (CDC) reported largely similar paraben, BPA and phthalate levels in the United States of America18.
The direct and inverse associations between parabens and adiposity-related traits which we observed in this 
study did not reach significance. A recent study by Kolatorova et al. showed higher concentrations of MeP and PrP 
in serum of obese compared to normal-weight individuals65, supporting the findings in a large Korean cohort66. 
Yet, a large cross-sectional study including 4,730 adults from NHANES found inverse associations between par-
abens and adiposity36. Therefore, research is needed in prospective populations to further investigate the effects 
of parabens on adiposity.
Abbreviation
N > LOD 
(%)
N > LOQ 
(%)
Raw values (ng/mL) Volume-adjusted values (µg/24 h)
Median [Q25, Q75] max Median [Q25, Q75] max
Parabens (nmol) 437 [100; 1259) 75420
Methyl paraben MeP 662 (100) 654 (99) 26.85 [5.8; 76] 4079 48.5 [10; 129] 8134
Ethyl paraben EtP 649 (98) 507 (77) 1.68 [0.53; 7.3] 488 2.95 [1.0; 12.7] 620
Propyl paraben PrP 617 (93) 427 (65) 2.70 [0.5; 20] 1963 4.61 [0.8; 37] 3914
n-Butyl paraben n-BuP 571 (86) 135 (20) 0.16 [0.1; 0.7] 64.5 0.29 [0.1; 1.2] 188
Benzyl paraben BzP 36 (5) 0 (0) <LOD [ < LOD; < LOD] 0.71 <LOD [ < LOD; < LOD] 3.37
Bisphenols (nmol) 19.8 [9.96; 36.2] 574
Bisphenol A BPA 628 (95) 410 (62) 1.9 [0.96; 3.63] 54.4 3.31 [1.6; 6.5] 130
Bisphenol F BPF 342 (52) 85 (13) 0.24 [<LOD; 0.68] 56.4 0.28 [<LOD; 1.2] 78.2
Bisphenol S BPS 59 (9) 10 (2) <LOD [ < LOD; < LOD] 4.06 <LOD [ < LOD; < LOD] 9.64
Phthalates
Low Molecular Weight-phthalates (nmol) 880 [504; 1727] 47154
Mono-methyl phthalate MMP 349 (53) 76 (11) 0.48 [<LOD; 1.2] 37.6 0.66 [<LOD; 1.9] 38.1
Mono-ethyl phthalate MEP 661 (100) 661 (100) 47.1 [20; 132] 6635 83.5 [34; 247] 8950
Mono-iso-butyl phthalate MiBP 662 (100) 662 (100) 19.7 [12; 34] 389 33.0 [24; 51] 493
Mono-n-butyl phthalate MnBP 662 (100) 662 (100) 17.5 [11; 29] 367 31.0 [20; 45] 760
High Molecular Weight-phthalates (nmol) 220 [153; 305] 4798
Di-(2-ethyl-hexyl) phthalate (nmol) DEHP 165 [118; 229] 4737
Mono-(2-ethylhexyl) phthalate MEHP 556 (84) 343 (52) 2.07 [1.0; 3.7] 50.5 3.96 [1.7; 6.3] 104
Mono-n-hexyl phthalate MnHP 140 (21) 23 (3) <LOD [ < LOD; < LOD] 18.2 <LOD [ < LOD; < LOD] 30.9
Mono-(2-ethyl-5-hydroxyhexyl) phthalate MEHHP 662 (100) 662 (100) 9.12 [6.2; 14] 183 16.0 [11; 23] 377
Mono-(2-ethyl-5-oxohexyl) phthalate MEOHP 662 (100) 660 (100) 6.15 [4.1; 9.6] 146 11.0 [7.6; 16] 301
Mono-(2-ethyl-5-carboxypentyl) phthalate MECPP 662 (100) 662 (100) 10.3 [6.6; 16] 307 17.59 [12; 25] 633
Mono-benzyl phthalate MBzP 662 (100) 639 (97) 5.84 [3.3; 11] 617 9.95 [5.9; 18] 360
Mono-iso-nonyl phthalate MiNP 5 (1) 4 (1) <LOD [ < LOD; < LOD] 5.31 <LOD [ < LOD; < LOD] 13.9
Mono-hydroxy-iso-nonyl phthalate MiDP 63 (10) 2 (0) <LOD [ < LOD; < LOD] 2.90 <LOD [ < LOD; < LOD] 7.58
Table 2. Urinary excretion of individual Endocrine Disrupting Chemicals, and grouped Endocrine Disrupting 
Chemicals. Abbreviations: h, hour; LOD, limit of detection; LOQ, limit of quantification; min, minimum 
(lowest detected concentration); Q25, 25th quartile; Q75, 75th quartile; max, maximum (highest detected 
concentration). Total concentrations of parabens, bisphenols, low molecular weight- and high molecular 
weight-phthalates (including DEHP) were calculated by summing the molar concentrations of its respective 
chemicals. Mono-hydroxy-iso-nonyl phthalate (MHiNP) was detected > LOQ in none of the samples, and 
therefore not displayed.
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Figure 1. Multivariate associations between adiposity-related traits and urinary paraben, bisphenol and 
phthalate concentrations in the Lifelines population (n = 662). Data is presented as estimate [confidence 
interval] for two models. The base model (red) is corrected for age and sex. The full model (blue) is corrected 
for age, sex, education, smoking, diabetes status, physical activity and total caloric intake. Endocrine Disrupting 
Chemicals (EDCs) which were detected above the limit of quantification (LOQ) in at least 50% of the samples 
were included in analysis. EDCs were log10-transformed before analysis. For full names of EDCs, see Table 2. 
*raw p-value < 0.05 in full model; †Benjamini and Hochberg False Discovery Rate (FDR < 0.05) in full model.
Figure 2. Multivariate associations between lipid-related traits and urinary paraben, bisphenol and phthalate 
concentrations in the Lifelines population (n = 662). Data is presented as estimate [confidence interval] for 
two models. The base model (red) is corrected for age and sex. The full model (blue) is corrected for age, sex, 
education, smoking, diabetes status, physical activity and total caloric intake. Endocrine Disrupting Chemicals 
(EDCs) which were detected above the limit of quantification (LOQ) in at least 50% of the samples were 
included in analysis. EDCs and triglycerides were log10-transformed before analysis. For full names of EDCs, see 
Table 2. *raw p-value < 0.05 in full model.
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A large body of evidence showed the obesogenic properties of BPA and phthalates67. In this study, we found 
associations between BPA and several phthalate metabolites (i.e. DEHP, MiBP, and MBzP) and adiposity related 
traits. Positive estimates for BPA and DEHP did not hold up after correction for multiple testing in the current 
study. However, other studies with larger sample sizes than the current study did report significant effects6,68. 
Associations found for MiBP and MBzP were in line with cross-sectional and prospective studies44,69–71.
Previously, BPA and phthalates have been linked to both impaired glucose metabolism6,11,37,72,73, as well as 
T2D26,47,73–75. In this study, we did not find any significant associations between EDCs and glycaemic traits. This 
could be explained by the observational design of this study in a healthy population (diabetic patients were 
excluded from glycaemic trait analysis) and insufficient statistical power to detect minor differences in a small 
range of glucose.
Evidence regarding associations between EDCs and lipid traits have been mixed. We detected an inverse asso-
ciation between MEHP and triglycerides, which did not remain significant after adjusting for multiple testing. 
Although Dong et al. showed higher urinary levels of MMP to be associated with hyperlipidemia, they also found 
an inverse association between MEHP and hyperlipidemia in line with our findings34. In contrast, James-Todd et 
al. found DEHP to be associated with hypertriglyceridemia6.
The relationship of EDCs with blood pressure traits remains unclear. Previously, several studies that investi-
gated associations between EDCs and blood pressure in pregnant women found inverse associations for parabens 
but direct associations with MBzP33,35. In a population of elderly people, MEP was inversely associated with dias-
tolic blood pressure37. We did not find any significant associations between EDCs and blood pressure.
Like natural hormones, EDCs have been shown to follow nonmonotonic dose-response curves48,49. When 
we tested associations between continuous EDCs and cardiometabolic traits in our main analysis, linearity was 
assumed. As it is possible that associations have non-linear effects, we assessed such potential non-linear associa-
tions by categorizing the EDCs of interest into quartiles. For all significant associations reported in the main anal-
ysis (using continuous EDCs), non-linear associations were not observed. However, some signs of non-linearity 
were found for blood pressure. Therefore, the findings for continuous EDCs and blood pressure should be inter-
preted with care.
The strengths of the current study include its population-based design, combined with objective anthropo-
metric measurements performed by a trained research nurse, extensive data on dietary intake and physical activ-
ity and measurements of EDC exposure in 24 h urine samples.
The Lifelines adult study population is broadly representative for the north of the Netherlands39 and the char-
acteristics of the current study population are comparable with the Dutch general population (i.e., similar age, 
sex-ratio and percentage of subjects with overweight; 45.8 versus 40.1 years; males: 42 versus 42%; overweight: 47 
versus 48%, respectively)76. This implies that our data reflect the EDC exposure in the Netherlands.
Due to the extensive data collected in the Lifelines cohort, we were able to adjust for confounding factors iden-
tified in earlier studies (i.e. age, sex, education, smoking, type 2 diabetes), as well as include traditional risk factors 
known to have adverse effects on cardiometabolic traits. Variables such as physical activity and caloric intake 
have a big impact on the cardiometabolic traits but are often not considered when investigating associations with 
EDCs. By including these lifestyle factors in the current study, we were able to test associations between EDCs and 
cardiometabolic traits while taking these classical risk factors into account.
In current study, EDCs levels were measured in urine collected over 24 h. It has been shown that parabens, 
BPA and phthalates are largely excreted in urine within 24 h after oral administration14–16. Moreover, urinary 
concentrations of parabens and phthalates increased in a few hours after topical application77. Due to this fast 
metabolism and excretion, 24 h urine samples provide a reliable estimate of exposure. While EDCs can also be 
measured in other biospecimens such as blood serum, adipose tissue and brain tissue78–81, its collection requires 
invasive methods and is time-consuming and expensive. Therefore, urine is the most suitable medium for the 
determination of these EDCs in large population studies.
As 24 h urine is relatively strenuous to obtain and requires motivated participants, many studies use spot- or 
morning-urine as proxy for chronic EDC exposure. In order to adjust these urinary EDC concentrations for 
dilution different techniques are used, mostly correcting for creatinine. Yet, creatinine levels vary by sex, age, 
race, diet, and activity82. Therefore, different techniques have shown to introduce inconsistencies in association 
analyses83. By using 24 h urine, urine dilution can be accounted for by multiplying raw EDC concentrations by 
the total volume of excreted urine to calculate urinary EDC excretion in mL/24 h. Therefore, it is expressed as an 
excretion rate (i.e. per-volume basis) and does not need additional adjustments82,84. Finally, the EDC concentra-
tions were quantified by LC-MS/MS presently regarded as the gold standard technique, providing accurate data 
on exposures.
Several studies include a multitude of chemicals, which are often limited to a single compound group (i.e. or 
parabens, or bisphenols, or phthalates). By using two LC-MS/MS methods, we were able to measure a broad set of 
EDC concentrations at the same time, covering the most common groups of non-persistent endocrine disruptors 
to which we are exposed in our daily life.
As this study is cross-sectional, results should be interpreted with caution. The direction of the associations 
found between EDCs and adiposity-related traits cannot be determined in the current design. Consequently, 
these data need to be confirmed in prospective studies. Our study population consisted of 662 subjects. Although 
this is a relatively big sample size when taking the collection of 24 h urine into account, associations between 
EDCs and cardiometabolic traits are often subtle, requiring a large power. In this study, many associations were 
found to be too weak to withstand correction for multiple testing. Therefore, larger studies are needed in the 
future.
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conclusions
In conclusion, we for the first-time assessed the exposure to the most common environmental chemicals such as 
parabens, bisphenols and phthalates in the Dutch population and evaluated its association with cardiometabolic 
profiles. Our data suggest obesogenic properties of some phthalates. These findings support the potency of EDCs 
to have clinically relevant effects on cardiometabolic health. Further research is warranted to expand our under-
standing of the impact of environmental chemicals on human health.
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